checkAd

Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes

Exscientia (Nasdaq: EXAI), the Medical University of Vienna and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, today announced publication in Cancer Discovery, a journal of the American Association of Cancer Research, of final results from the EXALT-1 trial. The study, titled Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Haematological Cancers and Identifies Exceptional Responders,” illustrates the potential real-world impact of using Exscientia’s AI-supported precision medicine platform (referred to in the study as single-cell functional precision medicine or scFPM) to propose which therapy would be most effective for late-stage haematological cancer patients based on testing drug responses ex vivo in their own tissue samples. Interim data from the study was previously published in The Lancet Haematology.

“Precision medicine is the right drug, for the right patient, at the right time. By enabling the robust and accurate assessment of drug effect on viable patient samples at single-cell resolution, we have created a technology that can provide hemato oncologists prediction of a patient’s response prior to deciding on a course of therapy,” said Gregory Vladimer, Ph.D., VP of translational research at Exscientia and co-inventor of the platform technology. “While the use of genetics in precision cancer medicine can determine if a target is present, functionally characterizing available drug options on patient cells within a short time window provides evidence for cancer cell sensitivity.”

"The EXALT-1 study was the first-ever prospective study of its kind, demonstrating the potential of a functional precision medicine platform to identify the optimal therapy for an individual patient. The results of the trial are clear: patients who were treated using recommendations guided by single-cell drug screenings from real-time biopsies remained progression-free longer as compared to their previous line of therapy,” commented Philipp P. Staber, M.D., Ph.D., haematologist oncologist at Medical University Vienna and principal investigator of the study.

The prospective, single-arm, open label EXALT-1 study was a basket trial for patients with a variety of aggressive haematological cancers. The study evaluated a total of 76 patients. Of these, 56 patients were treated according to scFPM and 20 patients received treatment based on physician’s choice. At a median follow-up of 23.9 months, 54% of patients (30/56) demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival (PFS) compared to their previous therapy, with 40% of responders (12/30) achieving exceptional responses lasting at least three times longer than expected for their respective disease. The PFS on scFPM-guided treatment was significantly increased (p=0.0093). Of note, 23% of patients (13/56) were progression-free after 12 months after scFPM-guided therapy, compared to only 5% of patients (3/56) on their previous treatment. The objective response rate was 55% for patients treated according to scFPM results.

Seite 1 von 3


Exscientia Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de

Wertpapier



50 Kommentare
Nachrichtenquelle: Business Wire (engl.)
11.10.2021, 22:01  |  481   |  50   |   

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Kommentare

Avatar
06.12.21 21:01:51
Es geht volatil zu , bin wieder leicht im Plus.
Mal sehen wie lange das so weitergeht.
Hoffe, es kommen mal Erfolgsmeldungen.👍
Avatar
06.12.21 18:03:38
Gut Ding braucht Weile, nicht umsonst hat MS bei der Evo Einschätzung mit Ziel 53€ auf KI hin gewiesen 😎🤠
Avatar
04.12.21 10:39:42
Tag Jungens...

Meine kleine Position hier ist seit kauf leider fast immer in rot 🙄.
Aber gut, geduldig sein ist hier und bei Evo leider eine notwendige Tugend.
Avatar
26.11.21 22:15:00
Oh, heute gingst ja runter 🥴
Avatar
19.11.21 17:57:11
Ich hoffe mal ,das Evotec hier teils beratend tätig wird, schließlich hat evotec Ahnung und Anteile.

Disclaimer

Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes Exscientia (Nasdaq: EXAI), the Medical University of Vienna and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, today announced publication in Cancer Discovery, a journal of the American Association of Cancer …

Nachrichten des Autors

Titel
Titel
Titel
Titel